top of page

研究成果 (論文掲載)

2026年

  1. Sakai H, Kusumoto-Matsuo R, Hosonaga M, Nozawa K, Futamura M, Tanabe Y, Mukohara T, Shiraishi K, Toyama T, Yasojima H, Watanabe N, Sakai H, Iwasa T, Takeuchi N1, Tada H, Sakai K, Chiba N, Takano T, Tsurutani J. BRCA1/2 Reversion Mutations in Japanese Patients with Metastatic Breast Cancer Progressing on Olaparib: OLIVE (WJOG15321B). Breast Cancer, 33(3):790-797, 2026

2025年

  1. Qian J, Watanabe T, Watanabe R, Kanno S, Takahashi A, Kohsaka S, Yoshino Y, Chiba N, Kohno T, Tanaka K, Yasui A, Ui A. BET family, BRD3 initiates DSB-induced chromatin remodeling with TIP60 to promote R-loop–mediated HR. Cell Reports, 44(11): 116461, 2025

  2. Yoshino Y, Ichimiya K, Jingu K, Fujita Y, Chiba N. Nicaraven enhances the cytotoxicity of X-ray irradiation in cancer cells with homologous recombination deficiency. Biochemical and Biophysical Research Communications, 742:151153, 2025

  3. Yoshino Y, Kikuta S, and Chiba N. Assay for Site-specific Homologous Recombination Activity in adherent cells, suspension cells, and tumor tissues. Bio-protocol, 15(7): e5260, 2025

2024年

  1. Motonari T, Yoshino Y*, Haruta M, Endo S, Sasaki S, Miyashita M, Tada H, Watanabe G, Naneko T, ishida T, Chiba N* (* co-corresponding authors). Evaluating homologous recombination activity in tissues to predict the risk of hereditary breast and ovarian cancer and olaparib sensitivity. Scientific Reports, 14: 7519, 2024

  2. Yoshino Y, Ogoh H, Iich Y, Sasaki T, Yoshida T, Ichimura S, Nakayama M, Wu X, Fujita H, Kikuchi M, Fang Z, Li X, Abe T, Futakuchi M, Nakamura Y, Watanabe T, Chiba N. Knockout of Brca1-interacting factor Ola1 in female mice induces tumors with estrogen suppressible centrosome amplification. BBA - Molecular Basis of Disease, 1870 (5) 167138, 2024

  3. Fang Z, Li X, Yoshino Y, Chiba N. Protocol to detect OLA1 polyubiquitination by Aurora A in vivo and in vitro. STAR Protocols, 5, 103008, June 21, 2024

  4. Yoshino Y, Fang Z, Chiba N. The centrosome: a critical hub for cell cycle regulation. Trends in Cell Biology, 34(6):437-439,2024

  5. Ikari T, Hiratsuka Y, Oishi T, Miyashita M, Morita T, Mack JW, Okada Y, Chiba N, Ishioka C, Inoue A. Preferred and Actual Places of Death Among Patients with Advanced Cancer: A Single-centre Cohort Study in Japan. Indian Journal of Palliative Care, 30:268-274, 2024

  6. Iida Y, Yanaihara N, Yoshino Y, Saito M, Saito R, Tabata J, Kawabata A, Takenaka M, Chiba N*, and Okamoto A*. (*co-last authors) Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway. Frontiers in Oncology, 14:1302850, 2024

2023年

  1. Fang Z, Li X*, Yoshino Y*, Suzuki M, Qi H, Murooka H, Katakai R, Shirota M, Thi Anh Pham M, Matsuzawa A, Otsuka K, Ishioka C, Mori T, Chiba N. (* equally contributed). Aurora A polyubiquitinates the BRCA1-interacting protein OLA1 to promote centrosome maturation. Cell Reports, 42(8):112850, 2023

  2. Yanaihara N, Yoshino Y, Noguchi D, Tabata J, Takenaka M, Iida Y, Saito M, Yanagida S, Iwamoto M, Kiyokawa T, Chiba N*, Okamoto A*. (*co-last authors) Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway. Gynecologic Oncology, 168:83-91, 2023

  3. Guo Q, Ji S, Takeuchi K, Urasaki W, Suzuki A, Iwasaki Y, Saito H, Xu Z, Arai M, Nakamura S, Momozawa Y, Chiba N, Miki Y, Matsuura M, Sunada S. Functional evaluation of BRCA1/2 variants of unknown significance with homologous recombination assay and integrative in silico prediction model. Journal of Human Genetics, 68, 849–857, 2023.

  4. Takahashi S, Ouchi K, Sakamoto Y, Mori T, Shimodaira H, Takahashi M, Ohori H, Kudo C, Takahashi Y, Imai H, Akiyama S, Takahashi M, Suto T, Murakawa Y, Oishi T, Isobe H, Okada Y, Kawai S, Yoshioka T, Sato T, Shindo Y, Sugiyama S, Komine K, Chiba N, Okita A, Yamaguchi T, Ishioka C. Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201. Journal of Gastrointestinal Oncology, 14(2):676-691, 2023

2022年

  1. Qi H, Kikuchi M*, Yoshino Y*, Fang Z, Ohashi K, Gotoh T, Ideta R, Ui A, Endo S, Otsuka K, Shindo N, Gonda K, Ishioka C, Chiba N. (* equally contributed). BRCA1 transports the DNA damage signal for CDDP-induced centrosome amplification through the centrosomal Aurora A. Cancer Science, 113(12):4230-4243, 2022

  2. Yoshioka T, Takahashi M, Sakamoto Y, Okita A, Fukui T, Murakawa Y, Shindo Y, Imai H, Ohori H, Shirota H, Chiba N, Ito Y, Nomura T, Fukushima N, Yamaguchi T, Shimodaira H, Ishioka C. Phase II study of cisplatin plus capecitabine after failure of adjuvant S-1 treatment in unresectable, metastatic gastric cancer (T-CORE1102) Anticancer Research, 42 (4):2009-2015, 2022

2021年

  1. Yoshino Y, Chiba N. Roles of RACK1 in centrosome regulation and carcinogenesis. Cellular Signaling, 90:110207, 2021

  2. Endo S*, Yoshino Y*, Shirota M, Watanabe G, Chiba N. (* co-first authors). BRCA1/ATF1-Mediated Transactivation is Involved in Resistance to PARP Inhibitors and Cisplatin. Cancer Research Communications, 1(2):90-105, 2021

  3. Yoshino Y, Fang Z, Qi H, Kobayashi A, Chiba N. Dysregulation of the centrosome induced by BRCA1 deficiency contributes to tissue-specific carcinogenesis. Cancer Science, 112(5):1629-1687, 2021

2020年

  1. Yoshino Y, Kobayashi A, Qi H, Endo S, Fang Z, Shindo K, Kanazawa R, Chiba N. RACK1 regulates centriole duplication through promoting the activation of polo-like kinase 1 by Aurora A. Journal of Cell Science, 133(17):jcs238931, 2020

  2. Otsuka K, Yoshino Y, Qi H, Chiba N. The function of BARD1 in centrosome regulation in cooperation with BRCA1/OLA1/RACK1. Genes, 11(8), 842, 2020

  3. Ui A, Chiba N, Yausui A. Interaction between transcription and DSB repair to prevent genome instability and cancer. Cancer Science, 111(5):1443-1451, 2020

2019年

  1. Yoshino Y*, Endo S*, Chen Z, Qi H, Watanabe G, Chiba N. (* co-first authors). Evaluation of site-specific homologous recombination activity of BRCA1 by direct quantitation of gene editing efficiency. Scientific Reports, 9:1644, 2019

  2. Yoshino Y, Qi H, Kanazawa R, Sugamata M, Suzuki K, Kobayashi A, Shindo K, Matsuzawa A, Shibata S, Endo S, Miyanishi Y, Shimaoka T, Ishioka C, Kanno S, Yasui A, Chiba N. RACK1 regulates centriole duplication by controlling localization of BRCA1 to the centrosome in mammary tissue-derived cells. Oncogene, 38(16):3077-3092, 2019

2018年

  1. Otsuka K, Takehara A, Chiba N, Matsui Y. Identification of KLF9 and BCL3 as transcription factors that enhance reprogramming of primordial germ cells. PLoS One, 13(10):e0205004, 2018

  2. Yoshino Y, H Qi, Fujita H, Shirota M, Abe S, Komiyama Y, Shindo K, Nakayama M, Matsuzawa A, Kobayashi A, Ogoh H, Watanabe T, Ishioka C and Chiba N. BRCA1-interacting protein OLA1 requires interaction with BARD1 to regulate centrosome number. Molecular Cancer Research, 16(10):1499-1511, 2018

  3. Kurosawa K, Inoue Y, Kakugawa Y, Yamashita Y, Kanazawa K, Kishimoto K, Nomura M, Momoi Y, Sato I, Chiba N, Suzuki M, Ogoh H, Yamada H, Miura K, Watanabe T, Tanuma N, Tachi M, Shima H. Loss of protein phosphatase 6 in mouse keratinocytes enhances K-rasG12D-driven tumor promotion. Cancer Science, 109(7):2178-2187. 2018

  4. Watanabe G, Chiba N, Nomizu T, Furuta A, Sato K, Miyashita M, Tada H, Ohuchi N, Ishida T. Increased centrosome number in BRCA-related breast cancer specimens determined by immunofluorescence analysis. Cancer Science, 109(6):2027-2035, 2018

2017年

  1. Takahashi M*, Chiba N*, Shimodaira H, Yoshino Y, Mori T, Sumii M, Nomizu T, Ishioka C. (* co-first author) OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer. Breast Cancer,  24(2):336-40, 2017

  2. Takahashi M, Komine K, Imai H, Okada K, Saijo K, Takahashi M, Shirota H, Ohori H, Takahashi S, Chiba N, Mori T, Shimodaira H, Ishioka C. Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with　unresectable or recurrent bone and soft tissue sarcoma: Results from a singleinstitutional analysis. PLoS One, 12(5):e0176972, 2017

2016年

  1. Fujita H, Yoshino Y, Chiba N. Regulation of centrosome cycle. Molecular and Cellular Oncology, e1075643, 2016

  2. Amin R, Morita-Fujimura Y, Tawarayama H, Semba K, Chiba N, Fukumoto M, Ikawa S. DNp63a induces quiescence and downregulates the BRCA1 pathway in Estrogen receptor-positive luminal breast cancer cell Line MCF7 but not in other breast cancer cell lines. Molecular Oncology, 10(4):575-93, 2016

2015年

  1. Kato H, Tanuma N, HayashiK, Kurosawa K, MomoiY, Ogoh H, Sakayori M, Kakugawa Y, Yamashita Y, Miura K, Ito S, Sato I, Chiba N, Watanabe T, and Shima H. Loss of Protein phosphatase 6 in mouse keratinocytes leads to increased susceptibility to ultraviolet-B-induced carcinogenesis. Cancer Letters, 1;365(2):223-8, 2015

  2. Mori T, Sumii, M, Fujishima F, Ueno K, Emi M, Nagasaki M, Ishioka C, Chiba N. Somatic alteration and depleted nuclear expression of BAP1 in human esophageal squamous cell carcinoma. Cancer Science, 106(9):1118-29, 2015

2014年

  1. Matsuzawa A, Kanno S, Nakayama M, Mochiduki H, Wei L, Shimaoka T, Furukawa Y, Kato K, Shibata S, Yasui A, Ishioka C, Chiba N. The BRCA1/BARD1-interacting protein OLA1 functions in centrosome regulation. Molecular Cell, 53:101-104, 2014

〜2013年

  1. Towler W I, Zhang J, Ransburgh D, Toland A, Ishioka C, Chiba N, Parvin J D. Analysis of BRCA1 variants in double strand break repair by homologous recombination and single strand annealing. Human Mutation, 34(3):439-445, 2013

  2. Kais Z, Chiba N, Ishioka C, Parvin J D. Functional differences among BRCA1 missense mutations in the control of centrosome duplication. Oncogene, 31(6):799-804 2012

  3. Wei L, Lan L, Yasui A, Tanaka K, Saijo M, Matsuzawa A, Kashiwagi R, Maseki E, Hu Y, Parvin J D, Ishioka C, Chiba N. BRCA1 contributes to transcription-coupled repair of DNA damage through polyubiquitination and degradation of Cockayne syndrome B protein. Cancer Science, 102(10):1840-1847, 2011

  4. Parvin J D, Chiba N, Ransburgh D. Identifying the effect of BRCA1 mutations on homologous recombination using cells that express endogenous wild-type BRCA1. Journal of Visualized Experiments, 48:2468, 2011

  5. Ransburgh D*, Chiba N*, Ishioka C, Toland A, Parvin J D. (*co-first author) Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination. Cancer Research, 70(3):988-995, 2010

  6. Wei L, Lan L, Hong Z, Yasui A, Ishioka C, Chiba N. Rapid recruitment of BRCA1 to DNA double-strand breaks is dependent on its association with Ku80. Molecular and Cellular Biology, 28(24);7380-93, 2008

  7. Starita L M, Howitz A A, Keogh M-C, Ishioka C, Parvin J D, Chiba N. BRCA1/BARD1 ubiquitinate phosphorylated RNA polymerase II. Journal of Biological Chemistry, 280(26):24498-505, 2005

  8. You F, Chiba N, Ishioka, C, Parvin, J D. Expresssion of an amino-terminal BRCA1 deletion mutant causes a dominant growth inhibition in MCF10A cells. Oncogene, 23(34):5792-8, 2004

  9. Chiba N, Parvin J D. The BRCA1 and BARD1 association with the RNA polymerase II holoenzyme. Cancer Research, 62:4222-28, 2002

  10. Chiba N, Parvin J D. Redistribution of BRCA1 among four different protein complexes following replication blockage. Journal of Biological Chemistry, 276(42):38549-54, 2001

​受賞

  1. 2025年5月31日　助教 方 震宙、公益財団法人 艮陵医学振興会 令和7年度勾坂記念賞 受賞　「分裂期キナーゼによるBRCA1結合分子のユビキチン化を介した中心体制御機構の解明」

  2. 2025年1月9日 助教 方 震宙、令和6年度東北医学会奨学賞A 受賞　「遺伝性腫瘍関連分子のユビキチン化による発がんメカニズムの解明」

  3. 2024年2月2日 助教 方 震宙、令和5年度東北大学加齢医学研究所 研究奨励賞 受賞

  4. 2021年10月2日 助教 方 震宙、80th JCA Annual Meeting Young Poster Award　「Aurora A-dependent ubiquitination of OLA1 regulates centrosome number via controlling the recruitment of PCM proteins. 」

  5. 2021年9月27日 助教 吉野優樹、第20回インテリジェント・コスモス奨励賞 受賞　「新規DNA損傷修復活性測定法を用いた遺伝性乳がんの機能的診断法の開発」

  6. 2021年4月19日 医学系研究科博士課程　遠藤栞乃、令和3年度 東北大学大学院医学系研究科女子大学院学生奨励賞七星賞 受賞「遺伝性乳がんの診断と抗がん剤感受性予測のためのDNA修復活性測定法の開発」

  7. 2020年5月16日 助教 吉野優樹、令和元年度 東北医学会 奨学賞A 受賞
    「がん抑制分子BRCA1によるゲノム安定性の維持機構の解明」

  8. 2020年1月31日  助教 吉野優樹、令和元年度 東北大学加齢医学研究所 研究奨励賞 受賞

  9. 2020年1月16日 助教 吉野優樹、公益財団法人艮陵医学振興会令和2年度匂坂記念賞 受賞　「遺伝性腫瘍原因分子によるゲノム安定性の維持機構の解明」

  10. 2019年11月8日　医学系研究科博士課程　遠藤栞乃、令和元年度 東北大学大学院医学系研究科辛酉優秀学生賞 特別賞 受賞
    「遺伝性乳がんの診断と抗がん剤感受性予測のためのDNA修復活性測定法の開発」

  11. 2019年9月27 日　教授 千葉奈津子、第78回日本癌学会学術総会　がん研究における女性研究者シンポジウム賞 受賞
    「新規BRCA1結合分子であるOLA1とRACK1は中心体複製を制御してゲノム安定性に寄与する」

​プレスリリース

  1. 2024 年4月9日　腫瘍組織や血液のDNA 損傷修復活性の測定法の開発

  2. 2023 年7月25日　細胞分裂を制御する酵素Aurora A が遺伝性乳がん関連分子を制御する新機構を発見

  3. 2022年9月16日　遺伝性乳がん・卵巣がん症候群の原因となるBRCA1の新たながん抑制能を発見

  4. 2021年11月12日　BRCA1 が関与するPARP 阻害薬の新たな耐性機序を発見

  5. 2019年2月8日　DNA損傷修復能の新しい測定法を開発

  6. 2019年1月11日　遺伝性乳がん・卵巣がん症候群の原因となるBRCA1の新規結合分子RACK1を発見

bottom of page